Form 4: Braden Leonard Sells 300k Aclaris Therapeutics Shares

Reporting person Braden M. Leonard sold 300,000 shares of Aclaris Therapeutics, Inc. (ACRS) at an average price of $4.53.

Summary

• Braden M. Leonard, a 10% owner of Aclaris Therapeutics, Inc., sold 300,000 shares of common stock.
• The transaction occurred on April 23, 2026, at a price of $4.53 per share.
• The shares were held indirectly through BML Investment Partners, L.P.
• Following the transaction, the reporting person maintains beneficial ownership of 13,950,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine divestment by a major shareholder rather than a fundamental change in company strategy.

Positives

• The reporting person retains a significant stake of 13,950,000 shares, indicating continued alignment with the company.

Negatives

• The sale of 300,000 shares by a 10% owner may be perceived by the market as a reduction in confidence or a liquidity event.

Risks

• Large block sales by major shareholders can exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling by 10% owners is common for portfolio rebalancing or liquidity purposes and does not necessarily reflect a negative outlook on the company's clinical or commercial prospects.

Comparison to Industry Standards

• The sale represents a small fraction of the total holdings of the reporting person, which is consistent with standard portfolio management practices for institutional investors.

Related Party Transactions

• The shares are held by BML Investment Partners, L.P., where Braden M. Leonard serves as the managing member of the general partner, BML Capital Management, LLC.

Stakeholder Impact

• Shareholders may experience minor volatility due to the volume of shares sold.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

ACRS, Aclaris Therapeutics, Insider Trading, Form 4, Braden Leonard, Equity Sale